Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/95085
DC FieldValueLanguage
dc.contributor.authorSvegliati-Baroni, Gianluca-
dc.contributor.authorGaggini, Melania-
dc.contributor.authorCarli, Fabrizia-
dc.contributor.authorBarbieri, Chiara-
dc.contributor.authorCucco, Monica-
dc.contributor.authorYoune, Ramy-
dc.contributor.authorRosso, Chiara-
dc.contributor.authorBugianesi, Elisabetta-
dc.contributor.authorGastaldelli, Amalia-
dc.date.accessioned2021-06-21T12:19:05Z-
dc.date.available2021-06-21T12:19:05Z-
dc.date.issued2020-06-
dc.identifier.issn1478-3223pt
dc.identifier.issn1478-3231pt
dc.identifier.urihttps://hdl.handle.net/10316/95085-
dc.description.abstractPatients with chronic liver disease (CLD), both non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC), are at high risk of diabetes (T2D), but mechanisms are still unknown. Muscle/liver insulin resistance (IR) and pancreatic dysfunction are the major metabolic defects leading to T2D. However, if the risk of T2D in CLD patients is because of reduced insulin response and/or to IR, and the impact of liver histology has not been investigated.pt
dc.language.isoengpt
dc.publisherWiley Online Librarypt
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/634413/EU/Elucidating Pathways of Steatohepatitispt
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/691042/EU/Mastiha treatment for healthy obese with NAFLD diagnosis (MAST4HEALTH).pt
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/72261pt
dc.rightsembargoedAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.titleMechanisms for increased risk of diabetes in chronic liver diseasespt
dc.typearticle-
degois.publication.firstPage2489-2499pt
degois.publication.lastPage2499pt
degois.publication.issue10pt
degois.publication.titleLiver Internationalpt
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/liv.14556pt
dc.peerreviewedyespt
dc.identifier.doi10.1111/liv.14556pt
degois.publication.volume40pt
dc.date.embargo2021-06-01*
uc.date.periodoEmbargo365pt
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.project.grantnoinfo:eu-repo/grantAgreement/EC/H2020/634413/EU/Elucidating Pathways of Steatohepatitis-
crisitem.project.grantnoFOIE GRAS -Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Fatty Liver Disease-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
paper HCV NAFLD beta cell LiverInt 2020.pdf706.78 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

11
checked on Sep 23, 2024

WEB OF SCIENCETM
Citations

12
checked on Sep 2, 2024

Page view(s)

142
checked on Oct 2, 2024

Download(s)

298
checked on Oct 2, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons